CBI’s mission is to improve global health by overcoming obstacles to the development and implementation of biomedical innovation. CBI provides a safe and transparent environment for collaborative research among industry, academia, and government, and draws on the expertise of the Massachusetts Institute of Technology’s (MIT) Schools of Engineering, Science, and Management, as well as the Harvard-MIT Division of Health Sciences and Technology (HST).
In this unique setting, CBI is addressing profound challenges in the global biomedical industry by developing, testing, and disseminating new knowledge and tools designed for real world application through the following programs: the Biomanufacturing Research Program (BioMAN), the Consortium on Adventitious Agents in Biomanufacturing (CAACB), New Drug Development Paradigms (NEWDIGS), and the Sanofi Biomedical Innovation Award Program (saBIP).
CBI was established in 2005 and in 2008, the Center merged with MIT’s Program on the Pharmaceutical Industry (POPI). POPI was founded in 1991 with a major grant from the Alfred P. Sloan Foundation to promote research and educational activities on issues related to competitiveness, performance and productivity in the pharmaceutical field.